← Eichor
Study identifier: NCT06168461 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Daily Aspirin Treatment After Preeclampsia

Condition: Preeclampsia  ·  Sponsor: Anna Stanhewicz, PhD

PhaseEARLY_Phase 1
Planned participants40
Who can joinFemale, 18 Years to 50 Years
Healthy volunteersNo

About this study

Women who develop preeclampsia during pregnancy are four times more likely to develop cardiovascular disease later in life, even if they are otherwise healthy. The reason why this occurs may be related to lasting blood vessel damage after the pregnancy but there are currently no specific treatment strategies to prevent this disease progression. This study addresses this public health issue by examining whether starting low dose aspirin therapy after pregnancy is an effective treatment for lasting blood vessel damage in order to inform better clinical management of cardiovascular disease risk in women who have had preeclampsia.

This description comes directly from the study's public registry record.

Talk to the study team

Anna Reid-Stanhewicz, PHD  ·  319-467-1732  ·  anna-stanhewicz@uiowa.edu

Always discuss trial participation with your own doctor first.

Locations (1)

University of IowaIowa City, Iowa, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06168461